Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12762493 | 1.00 | TSHR (0.52) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL21855325 | 1.00 | TSHR (0.52) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL26090976 | 1.00 | TSHR (0.52) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL3418676 | 1.00 | TSHR (0.52) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL19666667 | 1.00 | TSHR (0.52) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL9472095 | 0.98 | TSHR (0.55) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL3682553 | 0.91 | TSHR (0.63) | TSHRKMT2AMEN1HTTMAPT | |
| SCHEMBL4060095 | 0.88 | TSHR (0.67) | TSHRKMT2AMEN1HTTMAPT | |
| Triethylene Glycol SCHEMBL3729353 | 0.87 | TSHR (0.56) | TSHRKMT2AMEN1MAPK1HTT | |
| SCHEMBL8741176 | 0.87 | TSHR (0.56) | TSHRKMT2AMEN1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12448518-B2 | Phthalocyanine dye compounds, conjugates and methods of use thereof | Rakuten Medical, Inc. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240285765-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2024-08-29 | — | — | US | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4319817-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| EP-4132583-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022216978-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-11466158-B2 | Phthalocyanine dye compounds, conjugates and methods of use thereof | Rakuten Medical, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220010140-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2022-01-13 | — | — | US | disclosed |
| US-20220010140-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2022-01-13 | — | — | US | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2015070237-A1 | NEUROPROTECTIVE CHEMICALS AND METHODS FOR IDENTIFYING AND USING SAME | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | TSHR 331/4885KMT2A 1974/4885MEN1 940/4885 |
| US-11479556-B1 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | TSHR 4040/4885KMT2A 1161/4885MEN1 3115/4885 |
| US-20240285765-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | UACA, CD47, PITHD1 | TSHR 2527/4885KMT2A 2634/4885MEN1 1753/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | TSHR 4040/4885KMT2A 1161/4885MEN1 3115/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | TSHR 4040/4885KMT2A 1161/4885MEN1 3115/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | TSHR 3185/4885KMT2A 1005/4885MEN1 3270/4885 |
| US-11866442-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | CBL, XIAP, BTK | TSHR 4040/4885KMT2A 1161/4885MEN1 3115/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | TSHR 3211/4885KMT2A 904/4885MEN1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.